D
isturbances in ocular perfusion have been implicated in the pathophysiology of various eye diseases, including diabetic retinopathy, nonarteritic anterior ischemic optic neuropathy, and glaucoma. [1] [2] [3] [4] [5] [6] The ␣ 1 -adrenoceptor (␣ 1 -AR) family plays a critical role in regulating ocular vascular tone and blood flow by mediating vasoconstrictor responses of catecholamines in the ocular circulation. [7] [8] [9] [10] [11] Pharmacologic studies and molecular cloning techniques have revealed the existence of three ␣ 1 -AR subtypes: ␣ 1A , ␣ 1B , and ␣ 1D . [12] [13] [14] [15] [16] All three receptor subtypes are expressed in blood vessels and can mediate vasoconstriction via G q/11 protein-mediated increases of inositol phosphates and intracellular calcium in vascular smooth muscle cells. 17 However, the expression pattern of individual ␣ 1 -AR subtypes and their role in mediating vascular responses to catecholamines differs considerably between individual vascular beds. 18, 19 Based on these findings, selective pharmacologic activation or blockade of individual ␣ 1 -AR subtypes may provide a useful tool to selectively modulate perfusion of various organs, including the eye. Thus, we designed this study to identify the ␣ 1 -AR subtypes that mediate adrenergic vascular responses in ophthalmic arteries. Since the expression pattern of ␣ 1 -ARs is unknown in ocular vessels, we used real-time (RT) PCR to quantify mRNA expression of individual ␣ 1 -AR subtypes in murine ophthalmic arteries. Due to the lack of highly selective agonists and antagonists for individual ␣ 1 -AR subtypes, we used gene-targeted mice deficient in one of the three
, respectively) to determine the role of each receptor subtype in mediating adrenergic vasoconstriction in ophthalmic arteries.
MATERIALS AND METHODS

Animals
All studies were performed in accordance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the local government. The generation of ␣ 1A -AR Ϫ/Ϫ , ␣ 1B -AR Ϫ/Ϫ , and ␣ 1D -AR Ϫ/Ϫ mice has been described previously. 20 -22 Each genotype has been backcrossed with C57BL/6Slc mice for more than eight times and maintained on a C57BL/6Slc background. For experiments, male mice at the age of 7 to 9 months were used. Mice were fed with standard mouse chow and allowed free access to tap water.
Real-Time PCR Analysis
Expression of ␣ 1 -AR mRNA was quantified in isolated ophthalmic arteries from wild-type mice (C57BL/6Slc) using RT-PCR. After mice had been killed by CO 2 inhalation, the eyes were immediately removed together with the retrobulbar tissue and placed in ice-cold PBS (Invitrogen, Karlsruhe, Germany). Then, ophthalmic arteries were isolated by the use of fine-point tweezers under a dissecting microscope, transferred into a 1.5-mL tube, and immediately snap frozen. To increase the RNA yield, arteries were pooled from three mice. Subsequently, vessels were homogenized in lysis buffer using a homogenizing device (Schwingmühle MM 300; Retsch GmbH, Haan, Germany; Lysing Matrix D MP, MP Biomedicals, Illkirch, France). After homogenization, total RNA was extracted with a kit (Absolutely RNA Nanoprep; Stratagene, La Jolla, CA) according to the manufacturer's protocol. After complete DNA digestion, the RNA was reverse transcribed with the use of a reverse transcription kit and random hexamers (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Darmstadt, Germany). Quantitative PCR analysis was performed (GeneAmp StepOne Plus; Applied Biosystems). Nucleic acid stain (SYBR Green; Bioline, Luckenwalde, Germany) was used for the fluorescent detection of DNA generated during PCR. The PCR reaction was performed in a total volume of 12.5 L with 0.4 pmol/L of each primer and ready-to-use 2ϫ reaction mix (ImmoMix; Bioline); 2 L cDNA corresponding to 10 ng RNA was used as a template. Published sequences for mouse ␣ 1A -AR (NM_013461), ␣ 1B -AR (NM_007416), and ␣ 1D -AR (NM_013460) were used to design primers for PCR amplification. Primer sequences were ␣ 1A -AR sense 5Ј-TGC GAG GAC TGA AGG TCC GCT-3Ј and antisense 5Ј-CAG GGA CGC TGG GCG AAT GG-3Ј; ␣ 1B -AR sense 5Ј-TCC AGG GAA AAG AAA GCA GCC AA-3Ј and antisense 5Ј-GGG TAG ATG ATG GGG TTG AGG CA-3Ј; ␣ 1D -AR sense 5Ј-TAA GGC TGC TCA AGT TTT CCC GC-3Ј and antisense 5Ј-TGA GCG GGT TCA CAC AGC TAT TGA-3Ј; ß-actin sense 5Ј-CAC CCG CGA GCA CAG CTT CTT T-3Ј and antisense 5Ј-AAT ACA GCC CGG GGA GCA TC-3Ј. The expression levels of ␣ 1A -AR, ␣ 1B -AR, and ␣ 1D -AR mRNA were normalized to ß-actin using the ⌬Ct method. Parallelism of standard curves was confirmed.
Measurements of Vascular Reactivity
Mice were killed by CO 2 inhalation and the eyes were rapidly removed, together with the retrobulbar tissue, and placed in ice-cold Krebs buffer with the following ionic composition (in mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , and 11 glucose (Carl Roth GmbH, Karlsruhe, Germany). Then, ophthalmic arteries were isolated under a dissecting microscope, placed in an organ chamber filled with cold Krebs solution, and cannulated and sutured onto micropipettes, as described previously. 23 Vessels were pressurized via the micropipettes to 50 mm Hg under no-flow conditions using two reservoirs filled with Krebs solution and imaged using a video camera mounted on an inverted microscope; video sequences were captured to a personal computer for offline analysis. The organ chamber was continuously circulated with oxygenated and carbonated Krebs buffer at 37°C and pH 7.4. Arteries were allowed to equilibrate for 30 to 40 minutes before study. During this time, ophthalmic arteries of all groups developed spontaneous myogenic tone by constricting to 86% to 81% of initial diameter recorded immediately after pressurization. Reduction in luminal artery diameter during the equilibration period was similar in all four mouse genotypes. Viability of vessels was assessed as satisfactory when at least 50% constriction from stabilized resting diameter in response to high KCl solution (100 mM) was achieved. Then, cumulative concentration-response curves were obtained to phenylephrine (1 nM to 300 M), a non-subtype-selective ␣ 1 -AR agonist; to noradrenaline (1 nM to 300 M), a major neurotransmitter of sympathetic nerves; and to arginine vasopressin (AVP, 1 pM to 300 nM), a nonadrenergic receptor agonist, which induces vasoconstricton via V 1a -receptor-mediated increases of inositol phosphates and intracellular calcium in vascular smooth muscle. Responses to noradrenaline (10 M) were also compared before and after addition of prazosin (100 nM), a competitive non-subtype-selective ␣ 1 -AR antagonist.
Statistical Analysis
Data are presented as mean Ϯ SE and n represents the number of mice per group. Vascular responses are presented as percentage of change in diameter from stabilized resting diameter. Comparisons of concentration-response curves were made using the Brunner test for nonparametric analysis of longitudinal data. 24 The Bonferroni adjustment was used to correct for multiple comparisons. To compare vascular responses to noradrenaline before and after prazosin treatment, the Wilcoxon signed-rank test was used. Comparisons of ␣ 1 -AR mRNA expression levels were made using the Kruskal-Wallis test. The level of significance was set at 0.05.
RESULTS
␣ 1 -Adrenoceptor mRNA Expression in Ophthalmic Arteries
Expression of ␣ 1 -AR mRNA was determined in ophthalmic arteries (five pooled samples) from wild-type mice (n ϭ 15) by the use of quantitative RT-PCR. Remarkably, mRNA of all three ␣ 1 -AR subtypes was found to be expressed at high levels, although there was no difference between mRNA expression levels of individual receptor subtypes (Fig. 1) .
Responses of Ophthalmic Arteries
Ϫ/Ϫ , and wild-type mice to the non-subtype-selective ␣ 1 -AR agonist phenylephrine. Phenylephrine elicited concentrationdependent vasoconstriction in arteries from wild-type, ␣ 1B -AR Ϫ/Ϫ , and ␣ 1D -AR Ϫ/Ϫ mice that was similar in the three groups (Fig. 2) . Maximal reduction in luminal diameter in response to phenylephrine was 41% Ϯ 6%, 43% Ϯ 8%, and 38% Ϯ 4% in wild-type (n ϭ 10), ␣ 1B -AR Ϫ/Ϫ (n ϭ 8), and ␣ 1D -AR Ϫ/Ϫ (n ϭ 10) mice, respectively. The pD2 values (mean negative log of the vasoconstrictor concentration producing 50% of maximal response) were 5.79 Ϯ 0.16, 5.75 Ϯ 0.19, and 5.68 Ϯ 0.19 in wild-type, ␣ 1B -AR Ϫ/Ϫ , and ␣ 1D -AR Ϫ/Ϫ mice, respectively. In contrast, phenylephrine-induced vasconstriction was almost completely abolished in ophthalmic arteries from ␣ 1A -AR Ϫ/Ϫ mice (n ϭ 8), differing significantly from responses of all other genotypes. Maximal reduction in luminal diameter to phenylephrine was only 6% Ϯ 5% in this group (Fig. 2) .
Moreover, we examined responses to the sympathetic transmitter noradrenaline that, apart from ␣ 1 -ARs, can also activate ␣ 2 -ARs and ␤-ARs. Noradrenaline also produced concentrationdependent vasoconstriction in ophthalmic arteries from wild- , and ␣ 1D -AR Ϫ/Ϫ mice, respectively. In ␣ 1A -AR Ϫ/Ϫ mice (n ϭ 8), however, maximal reduction in luminal artery diameter in response to noradrenaline was negligible and differed significantly from responses of all other genotypes. Maximal reduction in luminal diameter was only 1% Ϯ 3% in this group (Fig. 3A) . After incubation with the competitive non-subtype-selective ␣ 1 -AR antagonist prazosin (100 nM), responses to noradrenaline (10 M) were negligible in all groups of mice (Fig. 3B) .
The nonadrenergic vasoconstrictor AVP elicited concentration-dependent vasoconstricton in ophthalmic arteries from all four mouse genotypes, which did not differ between individual groups (Fig. 4) . Maximal constriction to AVP was 48% Ϯ 8%, 49% Ϯ 8%, 52% Ϯ 8%, and 45% Ϯ 7% in wild-type (n ϭ 10), 
DISCUSSION
The purpose of the present study was to identify the ␣ 1 -AR subtypes that mediate adrenergic responses in ophthalmic arteries. Using RT-PCR, we found mRNA of all three ␣ 1 -AR subtypes to be expressed at similar levels in ophthalmic arteries of wild-type mice. Since highly selective agonists and antagonists are not available for all three subtypes, we used mice with targeted disruption of single ␣ 1 -AR subtype genes to assess the functional relevance of each receptor subtype. Strikingly, oph- thalmic arteries from mice deficient in the ␣ 1A -AR gene showed almost no reactivity to phenylephrine and noradrenaline. The ␣ 1 -AR antagonist prazosin almost completely abolished noradrenaline-induced responses, indicative of the predominant involvement of ␣ 1 -ARs in adrenergic vasoconstriction of ophthalmic arteries. Deletion of either receptor subtype did not affect vasoconstriction induced by AVP, suggesting that the lack of a single ␣ 1 -AR subtype does not affect the downstream signaling cascades that ultimately mediate vasoconstriction.
Previous studies using electrical stimulation of sympathetic nerve pathways and intravenous application of ␣ 1 -AR antagonists demonstrated that ␣ 1 -ARs mediate neurogenic vasoconstriction in the anterior choroid of rats and in long posterior ciliary arteries of cats. 8, 10 Another study using transmural electrical stimulation in isolated vascular strips showed that ␣ 1 -ARs contributed to neurogenic vasoconstriction in dog short posterior ciliary and ophthalmic arteries. 9 The present study is the first to demonstrate that adrenergic vasoconstriction of murine ophthalmic arteries is mediated predominantly by the ␣ 1A -AR subtype.
Earlier pharmacologic studies making use of subtype-selective agents and functional studies in gene-targeted mice lacking one or more ␣ 1 -AR subtypes revealed that the contribution of individual ␣ 1 -AR subtypes to adrenergic vasoconstrictor responses differs considerably depending on the vascular bed. Based on these studies, the ␣ 1A -AR is significantly involved in adrenergic vasoconstriction of rat and mouse small mesenteric and tail arteries, but plays only a minor role in ␣ 1 -AR-mediated contraction of large vessels, such as aorta, iliac, and carotid arteries. 18, 19, [25] [26] [27] In contrast, the ␣ 1D -AR was shown to play a major vasoconstrictor role in large vessels, but was also suggested to participate in ␣ 1 -AR-mediated vasoconstriction of some small arteries, such as coronary and femoral small arteries. 19, [27] [28] [29] [30] The ␣ 1B -AR was shown to play only a minor role in adrenergic vasoconstriction. In vivo studies have demonstrated that blood pressure responses to phenylephrine and to noradrenaline are reduced in gene-targeted mice lacking the ␣ 1B -AR. However, no differences in resting blood pressure between ␣ 1B -AR knockout and respective wild-type mice were detected. 21 Moreover, several in vitro studies using ␣ 1 -AR subtype-selective antagonists and mice with targeted disruption of the ␣ 1B -AR gene revealed only a minor contribution of the ␣ 1B -AR subtype to vasoconstrictor responses in mouse aorta, carotid, mesenteric, and tail arteries. 18, 21, 25 Studies of mRNA and protein expression revealed diverse distribution of ␣ 1 -AR receptor subtypes among vascular beds. 18, 19, 31 Some of these studies reported that the mRNA expression levels of individual ␣ 1 -AR subtypes were in fairly good agreement with their protein levels or their contribution to adrenergic vasoconstrictor responses. 18, 19, 31, 32 Other studies, however, demonstrated that the presence of mRNA or even protein for a particular ␣ 1 -AR subtype does not ensure its participation in vasoconstriction. 33, 34 This can be explained either by differences in the efficiency of individual ␣ 1 -AR subtypes to accumulate intracellular inositol phosphate and calcium or by a different extent of receptor subtype expression in intracellular compartments, preventing them from interaction with the hydrophilic natural ligands. 34 -36 Although we found mRNA of all three ␣ 1 -AR subtypes to be expressed at similar levels in ophthalmic arteries, adrenergic vasoconstriction was predominantly mediated by the ␣ 1A -AR, raising a question about the physiologic role of ␣ 1B -and ␣ 1D -ARs. A growing body of evidence suggests that each receptor subtype can activate independent signaling pathways, resulting in different physiologic functions. 15 For example, the ␣ 1D -AR was shown to mediate generation of reactive oxygen species and induction of apoptosis in human aortic smooth muscle cells. 37, 38 Moreover, the ␣ 1B -AR was reported to mediate trophic effects of catecholamines in mouse arteries, whereas the ␣ 1D -AR does not appear to be involved in this process. 39, 40 Thus, although our data indicate that ␣ 1B -and ␣ 1D -ARs do not significantly contribute to adrenergic vasoconstricton in murine ophthalmic arteries, both receptor subtypes may be involved in regulation of other physiologic or pathophysiologic actions.
In conclusion, our data provide evidence that the ␣ 1A -AR subtype mediates adrenergic vasoconstriction in murine ophthalmic arteries. From a clinical point of view, selective ␣ 1A -AR antagonists may become therapeutically useful to increase ocular perfusion in certain pathologic conditions, such as diabetic retinopathy and glaucoma. 1, 2, 5, 6 
